1. Scrip
  2. >>R&D

Promising Results In GSK Study Could Break Years Of TB Vaccine Deadlock

 
• By Jo Shorthouse

GlaxoSmithKline has published results from its latest Phase IIb trial of its investigational tuberculosis vaccine that show a subunit vaccine can reduce pulmonary TB, possibly leading the way for the first new vaccine for TB in over 90 years.

Vial

GlaxoSmithKline PLC’s tuberculosis candidate vaccine M72/AS01E, developed in alliance with non-profit organization Aeras Global TB Vaccine Foundation, has been shown to reduce pulmonary TB in HIV-negative adults with latent TB infection, in its latest Phase IIb trials.

The results published in the New England Journal of Medicine show a 54% efficacy for the vaccine, with an acceptable safety and reactogenicity profile. The study found varied response rates observed in different demographic sub-groups

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.